Boston Scientific Corp (BSX) concluded trading on Wednesday at a closing price of $99.40, with 8.45 million shares of worth about $840.29 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 10.36% during that period and on June 11, 2025 the price saw a gain of about 0.06%. Currently the company’s common shares owned by public are about 1.48B shares, out of which, 1.47B shares are available for trading.
Stock saw a price change of -2.96% in past 5 days and over the past one month there was a price change of -3.37%. Year-to-date (YTD), BSX shares are showing a performance of 11.29% which increased to 28.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $71.88 but also hit the highest price of $107.17 during that period. The average intraday trading volume for Boston Scientific Corp shares is 8.14 million. The stock is currently trading -4.17% below its 20-day simple moving average (SMA20), while that difference is down -1.38% for SMA50 and it goes to 5.43% higher than SMA200.
Boston Scientific Corp (NYSE: BSX) currently have 1.48B outstanding shares and institutions hold larger chunk of about 92.18% of that.
The stock has a current market capitalization of $147.06B and its 3Y-monthly beta is at 0.68. PE ratio of stock for trailing 12 months is 72.83, while it has posted earnings per share of $1.36 in the same period. Its PEG reads 5.21 and has Quick Ratio of 0.88 while making debt-to-equity ratio of 0.53. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BSX, volatility over the week remained 0.87% while standing at 1.05% over the month.
Stock’s fiscal year EPS is expected to rise by 16.33% while it is estimated to increase by 12.82% in next year. EPS is likely to grow at an annualized rate of 13.99% for next 5-years, compared to annual growth of -17.84% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Needham on April 16, 2025 offering a Buy rating for the stock and assigned a target price of $113 to it. Coverage by Deutsche Bank stated Boston Scientific Corp (BSX) stock as a Buy in their note to investors on January 10, 2025, suggesting a price target of $108 for the stock. On October 18, 2024, Needham Downgrade their recommendations, while on May 30, 2024, Goldman Initiated their ratings for the stock with a price target of $90. Stock get a Buy rating from Mizuho on February 01, 2024.
